Seliciclib (CYC202; r-roscovitine) in combination with cytotoxic agents in human uterine sarcoma cell lines

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Human leiomyosarcoma (LMS) is a malignancy with poor survival and chemo-resistance.
• Cell cycle deregulation is a hallmark of LMS.
• Targeting cyclin-dependent kinases (CDKs) is a promising strategy for cancer treatment.

Purpose of the Study:

• To investigate the efficacy of seliciclib, a CDK inhibitor, in combination with paclitaxel for uterine cancer treatment.
• To evaluate the synergistic effects and apoptotic impact of seliciclib and paclitaxel in uterine cancer cell lines.

Main Methods:

• Isobologram analysis and MTT chemosensitivity assays were employed.
• Cell lines were treated with seliciclib alone and in combination with paclitaxel.
• Apoptotic endpoints were assessed using Annexin V assays, flow cytometry, and Western blotting.

Main Results:

• Seliciclib and paclitaxel demonstrated synergistic effects across all tested uterine cancer cell lines.
• The combination therapy resulted in enhanced apoptosis.
• Downregulation of LAP survivin was observed.

Conclusions:

• The findings support the use of seliciclib in combination therapy for uterine cancer.
• Seliciclib shows potential as a therapeutic agent for uterine malignancies.
• Combination therapy may overcome chemo-resistance in uterine cancer.